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Strong predictive value 
of mannose-binding lectin levels 
for cardiovascular risk of hemodialysis patients
Felix Poppelaars1*† , Mariana Gaya da Costa1†, Stefan P. Berger1, Solmaz Assa2, Anita H. Meter‑Arkema1, 
Mohamed R. Daha1,3, Willem J. van Son1, Casper F. M. Franssen1 and Marc A. J. Seelen1
Abstract 
Background: Hemodialysis patients have higher rates of cardiovascular morbidity and mortality compared to the 
general population. Mannose‑binding lectin (MBL) plays an important role in the development of cardiovascular 
disease. In addition, hemodialysis alters MBL concentration and functional activity. The present study determines 
the predictive value of MBL levels for future cardiac events (C‑event), cardiovascular events (CV‑event) and all‑cause 
mortality in HD patients.
Methods: We conducted a prospective study of 107 patients on maintenance hemodialysis. Plasma MBL, properdin, 
C3d and sC5b‑9 was measured before and after one dialysis session. The association with future C‑events, CV‑events, 
and all‑cause mortality was evaluated using Cox regression models.
Results: During median follow‑up of 27 months, 36 participants developed 21 C‑events and 36 CV‑events, whereas 
37 patients died. The incidence of C‑events and CV‑events was significantly higher in patients with low MBL levels 
(<319 ng/mL, lower quartile). In fully adjusted models, low MBL level was independently associated with increased 
CV‑events (hazard ratio 3.98; 95 % CI 1.88–8.24; P < 0.001) and C‑events (hazard ratio 3.96; 95 % CI 1.49–10.54; 
P = 0.006). No association was found between low MBL levels and all‑cause mortality. Furthermore, MBL substantially 
improved risk prediction for CV‑events beyond currently used clinical markers.
Conclusions: Low MBL levels are associated with a higher risk for future C‑events and CV‑events. Therefore, MBL 
levels may help to identify hemodialysis patients who are at risk to develop cardiovascular disease.
Keywords: Complement, MBL, Cardiovascular, Risk, Hemodialysis
© 2016 The Author(s). This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Hemodialysis (HD) is a life-saving therapy for patients 
with end-stage renal disease. Despite modern technology 
and medicine, dialysis patients still have a poor progno-
sis [1]. Cardiovascular disease is the leading cause of both 
morbidity and mortality in patients receiving HD [2]. 
However, the mechanism behind cardiovascular disease 
in these patients might not be similar to those operating 
in the general population [3]. The clinical need for better 
predictors of cardiovascular disease in dialysis patients 
is on-going, since traditional risk factors are insufficient 
to explain their extensive cardiovascular risk. Dialysis 
patients have accelerated atherosclerosis. The chronic 
inflammatory state triggered by HD is thought to be 
partly responsible for the accelerated atherosclerosis in 
HD patients [4].
The complement system is an essential part of the innate 
immune system, but also plays a pivotal role in the patho-
genesis of a variety of diseases. It consists of three activa-
tion pathways; the classical pathway, the lectin pathway 
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the LP is mannose-binding lectin (MBL), which can inter-
act with different carbohydrate ligands found on patho-
gens, and on stressed or apoptotic cells [6, 7]. In the general 
population, there is a wide variation in plasma MBL levels, 
caused by genetic polymorphisms of the mbl2 gene [8]. 
MBL is also an acute phase protein and, therefore, levels 
can increase by two- to threefold during inflammation [9].
Considering the important role of innate immunity 
and its potent component MBL in inflammation, much 
attention has been paid to its role in the development 
of cardiovascular disease [10]. In clinical studies MBL 
has been associated with cardiovascular risk [11]. Low 
MBL levels as well as MBL deficiency-associated geno-
types have been reported to increase cardiovascular risk 
in healthy individuals, independently of traditional risk 
factors [12, 13]. Furthermore, higher MBL markedly 
decreased the risk for cardiac events in individuals with 
diabetes, hypercholesterolemia, or chronic inflammation. 
Remarkably, there was no difference in the cardiovascular 
risk between diabetic and nondiabetic patients with MBL 
titers above 1000  ng/mL [12]. Moreover, experimental 
studies have shown that MBL is involved in the patho-
physiology of atherosclerosis [14–16]. However, the rela-
tionship between MBL and disease is complex and MBL 
can be detrimental or beneficial depending on different 
genetic and environmental factors.
In HD patients, concentration and functional activity of 
MBL are altered compared to healthy controls [17]. MBL 
has also been shown to bind to the dialysis membrane 
during HD [18]. In addition, dialysis patients have signifi-
cantly reduced levels of functional (high order oligomers) 
MBL, while non-functional (low-order oligomers) MBL 
levels are increased [19]. The basic structural unit of MBL 
can oligomerizes to form dimers up to hexamers. Func-
tional MBL consists of higher order multimers (tetram-
ers, pentamers and hexamers) [8, 20, 21]. Only high order 
oligomers have the ability to bind carbohydrates and 
activate the LP. In contrast, monomers and low order 
oligomers (dimers and trimers) cannot efficiently bind 
carbohydrates and can therefore not activate the comple-
ment system. How dialysis impacts the oligomerisation of 
MBL remains unknown. Nevertheless, reports about the 
effects of MBL levels in HD patients on clinical outcome, 
such as cardiovascular events, are lacking.
We hypothesized that MBL levels adversely affect cardi-
ovascular risk in HD patients. Therefore, this study aimed 
to determine the predictive value of MBL levels for car-
diovascular events and all-cause mortality in HD patients.
Methods
Study population and design
A prospective study of 45  months was conducted in a 
cohort of 109 hemodialyses (HD) patients, recruited at 
the Dialysis Center Groningen and the University Medi-
cal Center Groningen. The protocol has been described 
previously [22]. In brief, patients were eligible for entry 
when they had been on HD therapy for more than 
3  months. Patients with severe heart failure (NYHA 
class IV) were excluded. In addition, two patients were 
excluded due to lack of plasma samples.
Dialysis settings
Patients were on a three-times weekly dialysis schedule 
using a low-flux polysulfone hollow-fiber dialyzer (F8; 
Fresenius Care, Bad Homburg, Germany). The tempera-
ture of the dialysate was 36.0 or 36.5  °C. Ultrafiltration 
rate was constant and blood and dialysate flows were 
250–350 and 500  mL/min, respectively. Blood samples 
were obtained at the start and end of a regular 4-h HD 
session.
Clinical and laboratory measurements
Relevant patient characteristics were extracted from 
patient records. More details of the cohort has been pub-
lished previously [22]. Clinical parameters were meas-
ured before and after dialysis. Ultrafiltration rate was 
calculated as described previously [23].
Laboratory measurements at baseline included hema-
tocrit, HbA1c, albumin, pH, calcium and phosphate, 
which were measured by routine laboratory procedures. 
High-sensitivity C-reactive protein (hsCRP) was meas-
ured with the CRP monoassay (Siemens Healthcare 
Diagnostics).
Plasma mannose‑binding lectin levels
Plasma mannose-binding lectin (MBL) levels were 
assessed by ELISA as described previously [24, 25]. In 
short, 96-well ELISA plates were coated overnight with 
the anti-MBL 3E7 antibody (Hycult, Uden, The Neth-
erlands). After blocking with 1  % BSA/PBS for 60  min, 
plasma EDTA samples were incubated in the coated 
wells. Next, wells were incubated with Dig-conjugated 
3E7. Detection of binding of Dig-conjugated antibodies 
was performed using HRP-conjugated sheep anti-Dig 
Abs (Fab fragments, Roche, Mannheim, Germany). The 
plate was washed in PBS Tween-20 (0.05  %) between 
each step. For visualization 3,3′,5,5′-Tetramethylben-
zidine (TMB) was added and the colorimetric reaction 
was stopped with H2SO4. Absorption was measured at 
450  nm. Plasma from 50 healthy volunteers served as 
controls.
Quantification of the antigenic levels of C3d, C3, Properdin 
and C5b‑9
Complement activation product C3d and C5b-9 were 
determined. Additionally, properdin and C3 plasma 
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concentrations were measured. Properdin, C3d, and 
sC5b-9 were measured as described earlier [24, 26, 27]. 
Quantitative antigenic assay for C3 was performed by 
the radial immunodiffusion technique with monospecific 
anti-sera [28]. Plasma from 35 healthy volunteers served 
as controls.
Definition of endpoint
The primary end-point was the time to the first C-event 
and CV-event. The secondary outcome was all-cause mor-
tality. C-event was defined as the occurrence of ischemic 
heart disease [unstable angina pectoris, myocardial infarc-
tion, Coronary Artery Bypass Grafting (CABG) and/or 
Percutaneous Coronary Intervention (PCI)], sudden car-
diac death and congestive heart failure. Acute myocar-
dial infarction was diagnosed if at least two of the three 
following criteria were met: clinical status, elevated heart 
enzymes, and EKG changes. CV-events were defined as 
cardiac, cerebrovascular or peripheral vascular events. 
Cerebrovascular events were defined as stroke, ischemic 
insult, or newly diagnosed >70  % stenosis of the extrac-
ranial carotid artery. Strokes and ischemic insults had to 
be verified by CT or MRI. Peripheral vascular disease was 
defined as having intermittent claudication with angio-
graphically or sonographically proven stenosis >50  % of 
the major arteries of the lower limbs or ulcers caused by 
atherosclerotic stenosis or surgery for this disorder. Trans-
plantation was a censoring event and the transplantation 
date was considered as the final follow-up date.
Statistics
Statistical analysis was performed using SPSS version 
22.0 (IBM Corporation, Chicago, IL, USA) and STATA 
version 14 (Statacorp, College Station, TX: StataCorp 
LP). Results are presented as mean  ±  standard devia-
tion for normally distributed data, median [IQR] for 
non-normally distributed data and total number of 
patients with percentage [n (%)] for nominal data. Dif-
ferences between groups were assessed with the student 
t test or the Mann–Whitney-U test for normally and 
not-normally distributed variables, respectively, and χ2 
test for categorical variables. The Wilcoxon signed-rank 
test was used to compare values before and after HD. 
Correlations were assessed by using Spearman’s correla-
tion. Log-rank tests were performed between groups to 
assess the difference in the incidence of C-events, CV-
events and all-cause mortality and associations were 
assessed by Cox proportional hazard regression. The 
Harrell’s C statistic was used to assess how well a model 
distinguishes between patients who develop a CV-event 
and those who do not, while taking follow-up time into 
account. When outcome is binary, the Harrell’s C sta-
tistic is the equivalent of the area under the ROC curve 
[29]. A value of “1” indicated perfect discrimination 
whereas the value “0.5” indicated a performance com-
parable to chance. The additional value of MBL levels, 
post-dialysis, was determined by the integrated dis-
crimination improvement (IDI), The IDI indicates the 
difference between model-based probabilities for events 
and non-events for the models with and without MBL 




This study included a total of 107 subjects on mainte-
nance hemodialysis (HD). There were 71 males and 36 
females and their age was 62.5 ± 15.6 years. At baseline, 
the duration of HD therapy was 25.5  months (IQR 8.5–
52.3 months). Hypertension was seen in 80 % of the sub-
jects and diabetes in 23 %. Previous cardiovascular event 
(CV-event) was documented in 40 % of patients, specifi-
cally myocardial infarction (14  %), previous PCI/CABG 
(19  %), unstable angina pectoris (3  %), cerebrovascular 
events (14 %), or peripheral vascular disease (5 %). Dur-
ing median follow-up of 27 months, 36 participants devel-
oped 21 C-events and 36 CV-events, whereas 37 patients 
died. The maximum follow-up period was 45 months.
MBL, properdin, C3d and C5b‑9 levels in hemodialysis 
patients
Mannose-binding lectin (MBL) levels were determined 
before starting and at the end of the HD session. Paired 
analysis of MBL levels revealed a modest, but significant 
increase in plasma concentration after HD (Fig. 1a). This 
is also shown by the post/pre-HD ratio of the MBL lev-
els (Fig. 1b). However, MBL levels were not significantly 
higher in HD patients compared to healthy controls 
(Table 1).
To determine the contribution of the alternative path-
way and complement activation, properdin, C3d and 
C5b-9 were analyzed. Properdin (Fig. 1c, d), C3d (Fig. 1e, 
f ) and C5b-9 (Fig. 1g–h) levels were significantly higher 
at the end of the HD session compared to the start, dem-
onstrating hemodialysis-induced complement activa-
tion. In accordance, spearman’s correlation revealed 
that C5b-9 levels correlated significantly with C3d levels 
(C5b-9/C3d, r = 0.367, P < 0.001), indicating that central 
complement activation is correlated with terminal com-
plement activation. Furthermore, properdin, C3d, and 
C5b-9 levels were significantly higher in HD patients 
than healthy controls (Table 1). However, properdin, C3d 
and C5b-9 levels were not correlated with MBL levels in 
HD patients (Properdin/MBL, r =  0.049, P =  0.6; C3d/
MBL, r  =  −0.031, P  =  0.7; C5b-9/MBL, r  =  −0.051, 
P = 0.6).
Page 4 of 12Poppelaars et al. J Transl Med  (2016) 14:236 
Page 5 of 12Poppelaars et al. J Transl Med  (2016) 14:236 
Hemodialysis patients with versus hemodialysis patients 
without cardiovascular events
To assess the effect of the complement system on cardio-
vascular risk, post-HD levels of patients who developed 
a CV-event during follow-up were compared to patients 
who did not. MBL levels were significantly lower in HD 
patients who developed a CV-event compared to HD 
patients without a CV-event (Table 1). Although not sig-
nificant, subjects with CV-events tended to have lower 
levels of properdin and higher C3d/C3-ratio’s and C5b-9 
levels than those without. We also found significant dif-
ferences in ultrafiltration volume, diabetes (incidence, as 
primary renal disease and in HbA1c), cardiovascular his-
tory, hsCRP and medication between subjects with and 
without CV-events (Additional file 1: Table S1).
For further analysis, we divided our study population 
into groups of low complement levels and high comple-
ment levels (Table 1). Since MBL levels were significantly 
(See figure on previous page.) 
Fig. 1 Patient plasma levels of mannose‑binding lectin, properdin, C3d and C5b‑9 before, after and relative change during hemodialysis. The distri‑
bution of plasma mannose‑binding lectin (MBL) (a), properdin (c), C3d (e) and sC5b‑9 (g) levels in healthy controls and hemodialysis (HD) patients 
at the start and end of the HD session. Horizontal lines indicate the median. The ratio for MBL (b), properdin (d), C3d (f) and sC5b‑9 (h) was calcu‑
lated per patient by dividing the pre‑HD level by the post‑HD level. Horizontal lines indicate the mean. A post/pre‑HD ratio higher than 1, indicates 
an increase in concentration during HD. Differences between healthy controls and HD patients were assessed with the Mann–Whitney‑U test. The 
Wilcoxon signed‑rank test was used to compare values before and after HD. (*P < 0.05, **P < 0.01, ***P < 0.001)
Table 1 Univariate analysis of MBL, properdin, C3, C3d and C5b-9
Values are expressed as median (interquartile range). Increased levels of MBL, properdin, C3d and C5b-9 were found at the end of hemodialysis compared with at the 
start of hemodialysis and controls. MBL was significantly lower in hemodialysis patients suffering from a cardiovascular event. An association was found between MBL 
and the cumulative incidence of a cardiovascular event
Italic values used to show which statistical testing was significant (below 0.05)
CV-event cardiovascular event; MBL mannose-binding lectin
a  Wilcoxon signed-rank test, at start hemodialysis vs. at end hemodialysis. All P-values are two-sided
b  Mann–Whitney test, at end hemodialysis vs. controls. All P-values are two-sided
c  Mann–Whitney test. All P-values are two-sided
d  Log-rank test
e  Split by lowest 25 %
f  Split by 400 ng/mL
g  Split by highest 25 %
Plasma concentration At start hemodialysis At end hemodialysis P‑valuea Controls P‑valueb
MBL 879 (255–1572) 821 (319–1477) 0.005 784 (277–1449) 0.9
Properdin 16.8 (13.6–22.4) 18.0 (14.2–23.8) 0.01 13.0 (10.8–14.7) <0.0001
C3d 7.3 (5.6–10.1) 10.3 (7.4–16.9) <0.0001 2.7 (2.3–3.4) <0.0001
C5b‑9 214 (166–419) 253 (187–487) <0.0001 141 (107–262) <0.0001
Plasma concentration No CV‑event CV‑event P‑valuec
MBL 1074 (428–1722) 464 (111–1102) 0.006
Properdin 18.6 (14.0–24.0) 17.3 (15.1–23.4) 0.8
C3d 10.3 (7.3–16.7) 10.8 (7.4–17.2) 0.8
C3d/C3 8.2 (6.3–13.7) 8.6 (6.0–15.6) 0.5
C3 1.28 (1.08–1.53) 1.32 (1.14–1.55) 0.6
C5b‑9 249 (182–513) 266 (194–473) 0.8
% CV event‑free survival Low level (%) High level (%) P‑valued
MBLe 42.30 74.10 0.003
MBLf 48.50 74.30 0.02
Properdine 65.40 74.10 0.6
C3dg 67.50 66.70 0.8
C3d/C3g 67.50 66.70 0.9
C3g 68.80 63.00 0.7
C5b‑9g 67.50 69.20 0.4
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lower in subjects with a CV-event, the 25th percentile 
was used as cut-off. This was also done for properdin lev-
els. Since C3d, C3, and C5b-9 levels were higher in sub-
jects with a CV-event, the 75th percentile was used as 
cut-off. Univariate regression analysis showed a signifi-
cant association between lower MBL levels and cardio-
vascular events. Of subjects with MBL levels below the 
25th percentile, 57.7 % developed a CV-event compared 
to 25.9 % of the subjects with MBL levels above the 25th 
percentile. Kaplan–Meier analysis revealed an increased 
incidence of both CV-events and C-event in HD patients 
with low MBL levels, but not all-cause mortality (Fig. 2). 
However, after exclusion of death by discontinuation of 
dialysis therapy (n = 7) and other causes (n = 2), a trend 
was seen for an increased mortality rate in HD patients 
with low MBL levels. Conversely, properdin, C3d, C3, 
C3d/C3-ratio and C5b-9 levels were not associated with 
C-events, CV-events and all-cause mortality in HD 
patients.
For additional analysis, patients were divided into 
two groups according to MBL levels using the cut-off 
of 400  ng/ml. This has earlier been shown to be closely 
related to MBL variant alleles, whereas MBL levels above 
400 ng/ml were related to MBL wild type [32]. A similar 
significant difference in the incidence of CV-events was 
observed using this cutoff. In our HD population, 30.8 % 
had MBL levels below 400 ng/ml and 69.2 % above, which 
is comparable to the frequency of variant alleles deter-
mined by others [33].
Cardiovascular risk according to MBL levels
We set out to further investigate the predictive value of 
plasma MBL levels for cardiovascular risk of HD patients. 
There was no significant difference in baseline charac-
teristics between the groups, according to MBL levels 
(Table  2). Furthermore, MBL levels correlated weakly 
with age (r  =  −0.26, P  =  0.007), post-dialysis systolic 
blood pressure (r = −0.24, P = 0.02) but not with high-
sensitivity C-reactive protein (hsCRP), body mass index 
(BMI), HbA1c and albumin (Table 2).
Multivariate analysis was performed to adjustment for 
potential confounders, including age and gender, char-
acteristics of HD (ultrafiltration volume and dialysis 
vintage), risk factors (cardiovascular history, diabetes, 
Fig. 2 Kaplan‑Meier curves for cardiovascular event, cardiac‑event and all‑cause mortality of hemodialysis patients with low or high mannose‑
binding lectin plasma levels. Cumulative event‑free survival for cardiovascular events (a), cardiac‑events (b), all‑cause mortality (c) and correct 
mortality (d) among hemodialysis patient (HD) with low and high mannose‑binding lectin (MBL) levels. Corrected mortality included cardiovascular, 
infectious and unknown mortality, while mortality for other reasons and discontinuation of dialysis therapy were excluded, Log‑rank test was used 
to compare the incidence of cardiovascular events, cardiac‑events and all‑cause mortality between the groups
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Table 2 Baseline characteristics of hemodialysis patients presented as groups according to MBL levels
Italic values used to show which statistical testing was significant (below 0.05)
BMI body mass index; ADPKD autosomal dominant polycystic kidney disease; FSGS focal segmental glomerulosclerosis; HbA1c Hemoglobin A1c; pH potential hydrogen; 
hsCRP high sensitive C-reactive protein; ACE inhibitor angiotensin-converting-enzyme inhibitor; AT2 receptor antagonists, Angiotensin II receptor antagonists
P* indicates P-value for the difference in baseline characteristics between the MBL groups, tested by Student’s t-Test or Mann–Whitney U test for continuous 
variables and with χ2 test for categorical variables; R indicates Spearman correlation coefficient between MBL levels and the baseline characteristic; # P indicates the 
corresponding P-value
Data are presented as mean ± SD or median [IQR]
MBL range (ng/mL) Patients P* < 0.001 R P#
All (n = 107) MBL low 319 <  ng/mL (n = 26) MBL high 319 ≥  ng/mL (n = 81)
821[319–1477] 98[33–146] 1290[671–1848]
Demographics
Age, years 62.5 ± 15.6 65.3 ± 12.1 61.56 ± 16.6 0.3 –0.26 0.007
Male gender, n (%) 71 (66) 17 (65) 54 (67) 1.0
Current diabetes, n (%) 25 (24) 9 (35) 16 (20) 0.2
Hypertension, n (%) 85 (84) 22 (88) 63 (83) 0.8
Cardiovascular history, n (%) 26 (25) 9 (35) 15 (19) 0.1
BMI, kg/m2 25.8 ± 4.4 27.0 ± 4.5 25.4 ± 4.4 0.1 –0.03 0.8
Hemodialysis
Dialysis vintage, months 25.5 [8.5–52.3] 18.2 [7.0–47.7] 32.8 [9.1–53.3] 0.2 –0.01 0.9
Primary renal disease, n (%)
Hypertension 18 (17) 4 (15) 14 (17) 1.0
Diabetes 14 (13) 5 (19) 9 (11) 0.3
ADPKD 13 (12) 3 (12) 10 (12) 1.0
FSGS 9 (8) 4 (15) 5 (6) 0.2
IgA nephropathy 4 (4) 0 (0) 4 (5) 0.6
Chronic pyelonephritis 3 (3) 0 (0) 3 (4) 1.0
Glomerulonephritis 13 (12) 2 (8) 11 (14) 0.7
Other diagnoses 16 (16) 6 (23) 10 (12) 0.2
Unknown 17 (16) 2 (8) 15 (19) 0.2
Ultrafiltration volume, L 2.55 ± 0.78 2.54 ± 0.82 2.56 ± 0.78 0.9 –0.01 0.9
Ultrafiltration rate, ml/kg/h 8.56 ± 2.63 7.81 ± 2.39 8.80 ± 2.67 0.1 0.04 0.7
Systolic blood pressure
Predialysis, mmHg 140.4 ± 25.1 144.7 ± 26.4 139.1 ± 24.7 0.3 –0.17 0.08
Postdialysis, mmHg 131.8 ± 25.6 136 ± 24.3 130.4 ± 26.0 0.4 –0.24 0.02
Heart rate
Predialysis, bpm 73 [63–82] 71 [62–82] 74 [64–82] 0.3 0.11 0.3
Postdialysis, bpm 79 [69–87] 75 [65–86] 79 [69–88] 0.4 0.13 0.2
Kidney transplant, n (%) 21 (20) 4 (15) 17 (21) 0.8
Laboratory measurements
Hematocrit,  % 34.9 ± 3.8 34.5 ± 4.1 35.0 ± 3.7 0.6 0.04 0.7
HbA1c, mmol/mol 5.68 ± 0.98 5.80 ± 0.97 5.63 ± 0.98 0.5 –0.15 0.2
Albumin, g/L 39 [37–42] 39 [37–42] 39 [37–42] 0.9 0.01 0.9
pH 7.37 [7.34–7.39] 7.37 [7.32–7.39] 7.37 [7.34–7.39] 0.7 0.05 0.6
Calcium, mmol/L 2.31 ± 0.16 2.31 ± 0.15 2.32 ± 0.16 0.9 0.03 0.7
Phosphate, mmol/L 1.67 ± 0.53 1.82 ± 0.47 1.65 ± 0.54 0.2 –0.00 0.9
hsCRP, mg/L 6.7 [2.8–10.9] 6.1 [1.4–12.0] 6.7 [3.0–10.9] 0.7 0.10 0.3
Medication
Aspirin, n (%) 57 (54) 11 (42) 46 (64) 0.3
Calcium channel blockers, n (%) 14 (13) 3 (12) 11 (14) 1.0
β‑Blocker, n (%) 61 (57) 18 (69) 43 (53) 0.2
ACE inhibitor, n (%) 10 (10) 3 (12) 7 (9) 0.7
AT2‑receptor antagonists, n (%) 14 (13) 2 (8) 12 (15) 0.5
Statin, n (%) 20 (19) 5 (19) 15 (19) 1.0
Diuretics, n (%) 8 (8) 3 (12) 5 (6) 0.4
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and systolic blood pressure) and inflammation (hsCRP) 
(Table 3). In the crude model, Low MBL levels were asso-
ciated with a hazard ratio of 2.64 (95  % CI 1.36–5.13; 
P = 0.004) for a CV-event and 2.60 (95 % CI 1.10–6.18; 
P  =  0.03) for a C-event. After adjustment, the hazard 
ratio for future CV-event was 3.98 (95  %CI 1.88–8.24; 
P  <  0.001) or 3.96 (95  % CI 1.49–10.54; P =  0.006) for 
C-event in HD patients with low MBL levels. In the 
unadjusted and adjusted models, these associations were 
also significant for plasma MBL levels as a continuous 
variable. Subsequently, analysis of the type of CV-events 
revealed that HD patients with low MBL levels are more 
prone to develop CV-events related to atherosclerosis, 
but not congestive heart failure (Table  4). In addition, 
the percentage of cardiovascular deaths was 15 % in the 
low MBL group compared to 9 % in the high MBL group 
(Table 4).
Predictive Value of MBL
The additional value of MBL for risk prediction of car-
diovascular events was assessed (Table  5). The Harrell’s 
C statistic was used to investigate the capability of each 
model to predict cardiovascular events and to compare 
the additional value of MBL levels in the different mod-
els. Plasma MBL alone had a Harrell’s C of 0.64 (0.54–
0.75). Furthermore, Harrell’s C in Table 5 show that the 
more variables we adjusted for, the better the model 
predicted cardiovascular events. The models contain-
ing MBL improved significantly according to the inte-
grated discrimination improvement index (IDI). Even in 
the fully adjusted models, the IDI value was >2 %, indi-
cating that MBL substantially improved risk prediction 
for cardiovascular events beyond currently used clinical 
markers.
Discussion
We found that lower plasma mannose-binding lectin 
(MBL) levels are associated with a higher incidence 
of cardiac (C-event) and cardiovascular events (CV-
event) in hemodialysis (HD) patients. In both unad-
justed and adjusted models, these associations were 
observed after a maximum follow-up of 45 months and 
were independent of established risk factors. Extending 
these findings, the higher cardiovascular risk for HD 
patients with low MBL levels seems to be attributed 
to CV-events linked to atherosclerosis. No significant 
association was found between MBL levels and all-
cause mortality, but a trend was visible for corrected 
mortality. For the first time, evidence is provided that 
MBL levels are a potent predictor of cardiovascular risk 
in patients on maintenance HD. Even in fully adjusted 
models, MBL substantially improved risk prediction for 
Table 3 Associations of MBL levels with cardiovascular events and cardiac events in 107 chronic hemodialysis patients
Model 1: crude
Model 2: adjusted for age and gender
Model 3: adjusted for model 2 plus ultrafiltration volume and dialysis vintage
Model 4: adjusted for model 3 plus cardiovascular history, diabetes and post-HD systolic blood pressure
Model 5: adjusted for model 4 plus hsCRP
Data are presented as hazard ratio (HR) plus 95 % confidence interval (CI) according to the cut-off of MBL and per standard deviation (SD) MBL decrease
Italic values used to show which statistical testing was significant (below 0.05)
MBL mannose-binding lectin; HD hemodialysis; hsCRP high sensitive C-reactive protein
Cardiovascular events
Low MBL Log MBL continuous
HR 95 % CI P HR (per SD) 95 % CI P
Model 1 2.64 1.36–5.13 0.004 0.64 0.46–0.90 0.01
Model 2 2.75 1.39–5.44 0.004 0.61 0.43–0.88 0.008
Model 3 2.94 1.45–5.94 0.003 0.61 0.42–0.89 0.01
Model 4 3.55 1.70–7.40 0.001 0.58 0.40–0.84 0.004
Model 5 3.98 1.88–8.42 <0.001 0.56 0.38–0.81 0.002
Cardiac events
Model 1 2.60 1.10–6.18 0.03 0.71 0.46–1.10 0.1
Model 2 2.49 1.04–5.96 0.04 0.73 0.46–1.16 0.2
Model 3 2.65 1.08–6.55 0.03 0.74 0.47–1.18 0.2
Model 4 3.82 1.48–9.87 0.006 0.62 0.38–1.01 0.06
Model 5 3.96 1.49–10.54 0.006 0.59 0.35–0.98 0.04
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cardiovascular events beyond currently used clinical 
markers. These results suggest that MBL has a consid-
erable influence on the pathophysiology of CV-events 
in HD patients and that low levels of MBL are unfa-
vorable for these patients.
Cardiovascular morbidity and mortality in HD 
patients is excessively high, with rates that are 10- to 
20-fold greater than in the general population [2]. In 
HD patients, traditional risk factors for cardiovascular 
disease are often found to be related to outcome in an 
opposite direction, which has been referred to as “reverse 
epidemiology” [3]. To improve risk stratification and our 
understanding of the causes of cardiovascular disease in 
these patients, the emphasis has been placed on finding 
better predictors of cardiovascular morbidity and mor-
tality. The association between MBL and CV-events has 
previously been reported in both the healthy population 
[12] and in diseases such as diabetes [34] and rheumatoid 
arthritis [35]. Both mbl2 genotype and MBL levels have 
been associated with increased risk for CV-event. How-
ever, the role of MBL in cardiovascular disease cannot 
be unequivocally defined, since MBL can be either det-
rimental or beneficial [10]. In our study, low MBL levels 
were associated with future CV-events, suggesting a ben-
eficial role for MBL in HD.
Circulating MBL levels are largely determined by the 
mbl2 gene and levels vary greatly from person to person 
due to frequently occurring polymorphisms [8]. The inci-
dence of MBL deficiency varies among populations [21]. 
Additionally, MBL levels are influenced by other factors 
such as age, sex, and lifestyle. In mice, MBL levels and 
functionality are different between genders, however, 
these findings have not been confirmed in humans [36, 
37]. Others have shown that MBL levels decline with 
age [37, 38]. Moreover, lifestyle factors can also impact 
MBL. Fasting and dietary restrictions reduce circulating 
levels of MBL as well as mRNA expression in liver [39], 
However, after adjustment for these confounders, MBL 
levels remained associated with cardiovascular events, 
indicating a direct and independent effect of MBL on 
cardiovascular risk. This study revealed that MBL levels 
are the same in HD patients and healthy controls. The 
Table 4 Type of cardiovascular events and cause of death in hemodialysis patients
Data are given as an absolute number of cardiovascular events or cause of death and as a percentage (%) of the total number of HD patients in each MBL group
CABG coronary artery bypass graft; PCI percutaneous coronary intervention; CVA cerebrovascular accident
Cardiovascular events
Acute coronary syndrome CABG/PCI Congestive heart failure Sudden death CVA Peripheral vascular disease
Low MBL levels 4 (15 %) 5 (19 %) 0 (0 %) 2 (8 %) 2 (8 %) 4 (15 %)
High MBL levels 4 (5 %) 5 (6 %) 3 (4 %) 3 (4 %) 2 (2 %) 8 (10 %)
Mortality
Cardiovascular Infection Stopping dialysis therapy Others Unknown
Low MBL levels 4 (15 %) 1 (4 %) 0 (0 %) 0 (0 %) 6 (23 %)
High MBL levels 7 (9 %) 1 (1 %) 7 (9 %) 2 (2 %) 9 (11 %)
Table 5 Additive value of plasma MBL for the prediction of cardiovascular events in hemodialysis patients
Data are presented as Harrell’s concordance statistic (Harrell’s C) with 95 % confidence interval (CI) and integrated discrimination improvement (IDI) with P-value (P)
Model 1: age and gender
Model 2: age, gender, ultrafiltration volume and dialysis vintage
Model 3: age, gender, ultrafiltration volume and dialysis vintage, history of CVD, DM and post-HD systolic blood pressure
Model 4: age, gender, ultrafiltration volume and dialysis vintage, history of CVD, DM and post-HD systolic blood pressure and hsCRP
MBL mannose-binding lectin; CVD cardiovascular diseases; DM Diabetes Mellitus; HD hemodialysis; hsCRP high sensitive C-reactive protein
a Change in C-statistics compared to model without post-hemodialysis MBL levels
Harrell’s C (95 % CI) Change (95 % CI)a IDI (%) P
Without MBL With MBL
Model 1 0.56 (0.46–0.66) 0.64 (0.53–0.76) 0.085 (0.072–0.098) 5.93 0.01
Model 2 0.64 (0.55–0.73) 0.67 (0.57–0.77) 0.033 (0.028–0.038) 5.35 0.01
Model 3 0.71 (0.63–0.80) 0.74 (0.65–0.83) 0.027 (0.026–0.028) 6.05 0.01
Model 4 0.73 (0.64–0.82) 0.76 (0.68–0.85) 0.033 (0.033–0.033) 6.92 0.01
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mean MBL levels of 955  ng/mL in our healthy controls 
are comparable to the levels described previously [10]. 
There have been several reports about MBL levels in HD 
patients. Similar to us, Ishii et al. and found no difference 
in plasma concentration of MBL between HD patients 
and healthy controls [40], while other studies have pro-
vided opposite findings [17, 41]. These paradoxical results 
about MBL levels in HD patients are explained by differ-
ences in genetic background, race, primary renal disease 
and percentage of diabetic subjects of the HD population. 
Lastly, ELISA techniques used to determine MBL have to 
be taken into account [19]. Satomura et al. revealed that 
patients undergoing HD have significantly reduced levels 
of high order oligomers (functional) MBL, while the same 
patients have significantly increased levels of low-order 
oligomers (non-functional) MBL [41]. In a Dutch cohort 
of renal transplant recipients, MBL levels similar to our 
study were found in samples obtained prior to transplan-
tation [25]. Using the same MBL ELISA setup, they also 
concluded that MBL levels in HD patients are identical 
to healthy controls. In addition, we revealed that during 
HD, plasma MBL levels increase significantly. Although 
we are the first to show changes in MBL levels during 
an HD session, it has previously been shown that MBL 
levels of HD patients were significantly higher after 6 
and 12 months than at the start of HD therapy [17]. The 
increase in MBL concentration is, therefore, unlikely to 
be a cause of the ultrafiltration during dialysis.
Few studies evaluated the effect of MBL levels in HD 
patient on clinical outcome. Satomura et  al. showed 
that HD patients with low MBL levels had a signifi-
cantly higher all-cause mortality than patients with high 
MBL levels [42]. In contrast, we found no differences 
in all-cause mortality. A possible explanation could 
be the difference in the percentage of cardiovascular 
mortality. In their study, the majority of deaths (67  %) 
were cardiovascular; whereas in our study, the percent-
age of cardiovascular mortality was much lower (30  %). 
Non-cardiovascular mortality accounted for another 
30 percent in our study and the cause of death for the 
remaining 40 percent was unknown. However, the results 
of Satomura et  al. are in line with our finding that low 
MBL levels are detrimental in HD patients. In addition, 
in our study the percentage of cardiovascular deaths was 
higher in low MBL group. Recently, it was demonstrated 
that higher levels of C3 at baseline are associated with 
an increased risk of CV-events [43]. In accordance, we 
found higher levels of C3 in HD patients who developed a 
CV-event compared to HD patients without a CV-event. 
However, this was not significant, but this is most likely 
due to the smaller sample size of our study.
It has become clear that MBL is associated with car-
diovascular disease. However, the relationship between 
MBL and disease is rather complex. Data obtained by 
clinical studies have been contradictory, MBL was some-
times protective and, at other times harmful. A possible 
explanation for this ambiguous role can be found in the 
different effector functions of MBL [44]. Whether these 
effector functions exhibit positive or negative effects in 
cardiovascular diseases depends on various elements, 
such as accompanying pathology, other risk factors, 
age, and sex. For instance, complement activation and 
thrombus formation via MBL [45] could be detrimental 
whereas opsonization and recognition of altered self/
apoptosis by MBL would be beneficial. We postulate that 
in HD patients, low MBL levels increase cardiovascu-
lar risk by promoting atherosclerosis due to the defec-
tive removal of atherogenic particles. This hypothesis 
is supported by evidence from previous studies show-
ing that MBL deficient subjects have worse and accel-
erated atherosclerosis [46, 47]. Furthermore, MBL is 
locally expressed during atherogenesis and negatively 
regulated the development of these lesions [14]. MBL is 
also involved in the removal of atherogenic particles and 
deficiency subsequently leads to accumulation of these 
particles [15, 16]. In patients with end-stage renal fail-
ure, low MBL levels have been linked to higher arterial 
stiffness [48].
Our study has limitations and strengths. Although 
causality of the associations found is likely, it cannot be 
proven since our study is prospective but observational 
in nature. We are aware that the proposed mechanisms 
described here are only speculative. Furthermore, in our 
HD patients genotyping of the mbl2 gene was not per-
formed due to the lack of DNA. MBL is an acute phase 
protein, so the plasma concentration increases substan-
tially during inflammation [9]. We cannot determine 
if the low MBL level in HD patients was due to genetic 
background or an insufficient inflammatory response. 
However, the lack of correlation with CRP is an argument 
against this. Finally, the population size is relatively small, 
limiting our power to detect all but the strongest associa-
tions between complement and cardiovascular risk. Neg-
ative findings should be interpreted with caution due to 
the risk of false negative associations. On the other hand, 
strengths include the long follow-up and uniform single-
center handling of samples along with the hard and clini-
cally relevant endpoints (C-events and CV-events).
Conclusion
In summary, measurement of plasma MBL level may 
proof to be a novel diagnostic tool and functional bio-
marker of cardiac and cardiovascular risk in HD patients, 
which may substantially improve prognostication. Inter-
vention studies based on plasma MBL concentrations 
are required to clarify whether therapeutic targeting 
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improves the cardiovascular risk of patients on mainte-
nance HD.
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